Literature DB >> 20859336

Even more cost savings?

James L Gulley, William D Figg, William Dahut.   

Abstract

Year:  2006        PMID： 20859336      PMCID： PMC2793602          DOI： 10.1200/JOP.2006.2.4.202

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  8 in total

1.  Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.

Authors:  Jennifer A Wagmiller; Jennifer J Griggs; Andrew W Dick; Deepak M Sahasrabudhe
Journal:  J Oncol Pract       Date:  2006-03       Impact factor: 3.840

2.  Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.

Authors:  Michael G Oefelein
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.

Authors:  James L Gulley; William D Figg; Seth M Steinberg; Jane Carter; Oliver Sartor; Celestia S Higano; Daniel P Petrylak; Gerkamal Chatta; Maha H Hussain; William L Dahut
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

4.  A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.

Authors:  R J Nejat; H H Rashid; E Bagiella; A E Katz; M C Benson
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

5.  A retrospective study of the time to clinical endpoints for advanced prostate cancer.

Authors:  Nima Sharifi; William L Dahut; Seth M Steinberg; William D Figg; Christopher Tarassoff; Philip Arlen; James L Gulley
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

6.  Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment.

Authors:  M G Oefelein
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.